GSA Capital Partners’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.96M | Buy |
31,294
+21,062
| +206% | +$1.68M | 0.12% | 178 |
|
|
2025
Q4 | $976K | Sell |
10,232
-8,803
| -46% | -$863K | 0.08% | 372 |
|
|
2025
Q3 | $1.86M | Buy |
19,035
+15,687
| +469% | +$1.62M | 0.15% | 100 |
|
|
2025
Q2 | $360K | Sell |
3,348
-780
| -19% | -$78.9K | 0.03% | 1149 |
|
|
2025
Q1 | $416K | Buy |
4,128
+829
| +25% | +$83.5K | 0.04% | 926 |
|
|
2024
Q4 | $295K | Buy |
+3,299
| New | +$290K | 0.02% | 1216 |
|
|
2022
Q3 | – | Sell |
-19,182
| Closed | -$715K | – | 1534 |
|
|
2022
Q2 | $715K | Buy |
+19,182
| New | +$781K | 0.11% | 291 |
|
|
2020
Q4 | – | Sell |
-7,531
| Closed | -$288K | – | 1229 |
|
|
2020
Q3 | $288K | Sell |
7,531
-144
| -2% | -$5.55K | 0.05% | 766 |
|
|
2020
Q2 | $269K | Buy |
+7,675
| New | +$276K | 0.15% | 218 |
|
|
2020
Q1 | – | Sell |
-9,220
| Closed | -$417K | – | 1084 |
|
|
2019
Q4 | $417K | Sell |
9,220
-5,646
| -38% | -$236K | 0.05% | 787 |
|
|
2019
Q3 | $605K | Buy |
+14,866
| New | +$630K | 0.08% | 433 |
|
|
2019
Q2 | – | Sell |
-15,955
| Closed | -$612K | – | 1452 |
|
|
2019
Q1 | $612K | Sell |
15,955
-686
| -4% | -$26.2K | 0.06% | 570 |
|
|
2018
Q4 | $588K | Buy |
+16,641
| New | +$604K | 0.07% | 475 |
|
|
2018
Q3 | – | Sell |
-10,838
| Closed | -$354K | – | 1640 |
|
|
2018
Q2 | $354K | Sell |
10,838
-1,829
| -14% | -$55.2K | 0.02% | 1315 |
|
|
2018
Q1 | $346K | Sell |
12,667
-90,193
| -88% | -$2.45M | 0.02% | 1251 |
|
|
2017
Q4 | $2.55M | Buy |
+102,860
| New | +$2.84M | 0.16% | 136 |
|
|
2017
Q3 | – | Sell |
-12,513
| Closed | -$347K | – | 1612 |
|
|
2017
Q2 | $347K | Buy |
12,513
+2,247
| +22% | +$59.6K | 0.02% | 1199 |
|
|
2017
Q1 | $255K | Buy |
+10,266
| New | +$250K | 0.01% | 1468 |
|
|
2016
Q4 | – | Sell |
-51,253
| Closed | -$1.22M | – | 1756 |
|
|
2016
Q3 | $1.22M | Buy |
51,253
+30,561
| +148% | +$729K | 0.07% | 496 |
|
|
2016
Q2 | $484K | Sell |
20,692
-57,053
| -73% | -$1.23M | 0.03% | 1093 |
|
|
2016
Q1 | $1.46M | Sell |
77,745
-29,407
| -27% | -$517K | 0.09% | 334 |
|
|
2015
Q4 | $1.98M | Buy |
+107,152
| New | +$1.92M | 0.1% | 257 |
|
|
2015
Q3 | – | Sell |
-54,803
| Closed | -$970K | – | 1754 |
|
|
2015
Q2 | $970K | Buy |
54,803
+13,200
| +32% | +$236K | 0.04% | 928 |
|
|
2015
Q1 | $738K | Buy |
+41,603
| New | +$657K | 0.03% | 1121 |
|
|
2014
Q4 | – | Sell |
-181,964
| Closed | -$2.15M | – | 1708 |
|
|
2014
Q3 | $2.15M | Sell |
181,964
-430,331
| -70% | -$5.42M | 0.11% | 177 |
|
|
2014
Q2 | $7.82M | Buy |
612,295
+579,511
| +1,768% | +$7.54M | 0.35% | 26 |
|
|
2014
Q1 | $443K | Sell |
32,784
-50,900
| -61% | -$668K | 0.03% | 868 |
|
|
2013
Q4 | $1.01M | Buy |
83,684
+48,437
| +137% | +$572K | 0.08% | 351 |
|
|
2013
Q3 | $414K | Sell |
35,247
-27,977
| -44% | -$303K | 0.03% | 919 |
|
|
2013
Q2 | $586K | Buy |
+63,224
| New | +$536K | 0.07% | 459 |
|
Other funds holding BSX
VCM
VPM
GSA Capital Partners's BSX Position: Q1 2026 in Review
GSA Capital Partners increased its Boston Scientific (BSX) stake by 206% in Q1 2026, buying an estimated $1.68M and bringing the position to 31,294 shares worth $1.96M. The position accounts for 0.12% of the portfolio, ranked #178.
GSA Capital Partners first reported a position in BSX in Q2 2013 and has held it in 30 quarters since. The position peaked at $7.82M in Q2 2014. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- GSA Capital Partners held 31,294 shares of Boston Scientific worth $1.96M as of Q1 2026.
- GSA Capital Partners bought 21,062 Boston Scientific shares in Q1 2026, an estimated $1.68M.
- Boston Scientific made up 0.12% of GSA Capital Partners's portfolio in Q1 2026, its #178 holding.
- GSA Capital Partners first reported a position in Boston Scientific in Q2 2013 and has held it in 30 quarters since.
- GSA Capital Partners's Boston Scientific position peaked at $7.82M in Q2 2014.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.